5Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician ,2003,67: 1959-1966.
6Major P , Lortholary A, Hon J ,et a1. Zoledronic acid is superior to pam?idronate in the treatment of hypercalcemia of malignancy: a pooled anal?ysis of two randomized, controlled clinical trials. J Clin Oncol, 2001 , 19:558-567.
7Kawada K, Minami H, Okabe K, et a1. A multicenter and open lahel clinical trial of zoledronic acid 4mg in patients with hypercalcemia of malignancy. Jpn J Clin Oncol,2005 ,35 :28-33.
9Bech A, Smolders K, Telting D, et al. Cinacalcet for hypercalcemia caused by pulmonary squamous cell carcinoma producing parathyroid hormone-related Peptide. Case Rep Oneal ,2012,5: 1-8.
10Stopeck AT, Lipton A, Body JJ, et a1. Denosumab compared with zole?dronic acid for the treatment of bone metastases in patients with ad?vanced breast cancer: a randomized, double-blind study. J Clin Oneal, 2010,28 :5132-5139.
2Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oneol, 2001, 19:558-567.
4Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate ( Zometa ). Kidney Int, 2003, 64:281-289.
5Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase Ⅲ, doubleblind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol, 2003, 21: 3150- 3157.
6Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, doubleblind, multicenter, comparative trial. Cancer, 2003, 98: 1735- 1744.
7Maxwell C, Swift R, Goode M, et al. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. Clin J Oncol Nurs, 2003,7:403-408.
8Pecherstorfer M, Jilch R, Sauty A, et al. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res, 2000, 15 : 147-154.
9Munns CF, Rauch F, Mier RJ, et al. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone, 2004, 35:231-234.
10Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol, 2003,135:219-222.
